Bicara Therapeutics (NASDAQ:BCAX) Trading Up 6.5% – What’s Next?

Bicara Therapeutics Inc. (NASDAQ:BCAX) shares rose 6.5% during trading on Friday . The stock traded as high as $15.95 and last traded at $16.4240. Approximately 24,865 shares were traded during trading, a decline of 94% from the average daily volume of 396,446 shares. The stock had previously closed at $15.42.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on BCAX shares. Wedbush reiterated an “outperform” rating and set a $30.00 price objective on shares of Bicara Therapeutics in a research note on Tuesday, January 13th. BTIG Research reaffirmed a “buy” rating on shares of Bicara Therapeutics in a research report on Thursday, January 15th. UBS Group restated a “buy” rating on shares of Bicara Therapeutics in a research note on Wednesday, January 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bicara Therapeutics in a report on Friday, January 9th. Finally, Mizuho upgraded shares of Bicara Therapeutics to a “hold” rating in a report on Thursday, December 18th. Seven research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $28.33.

Bicara Therapeutics Stock Performance

The firm has a market cap of $866.62 million, a price-to-earnings ratio of -7.04 and a beta of -0.79. The business’s 50 day moving average price is $16.57 and its 200 day moving average price is $15.26.

Insiders Place Their Bets

In other news, insider David Raben sold 5,500 shares of the business’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $18.45, for a total value of $101,475.00. Following the completion of the sale, the insider directly owned 35,497 shares in the company, valued at $654,919.65. The trade was a 13.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock in a transaction on Monday, December 15th. The shares were sold at an average price of $18.68, for a total transaction of $233,500.00. Following the completion of the sale, the chief operating officer directly owned 189,141 shares in the company, valued at $3,533,153.88. This represents a 6.20% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 82,817 shares of company stock worth $1,547,537. Company insiders own 15.50% of the company’s stock.

Institutional Trading of Bicara Therapeutics

Several large investors have recently made changes to their positions in BCAX. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Bicara Therapeutics in the 4th quarter valued at $45,000. Legal & General Group Plc lifted its position in Bicara Therapeutics by 64.1% in the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after buying an additional 1,233 shares during the last quarter. Ameritas Investment Partners Inc. boosted its stake in Bicara Therapeutics by 73.0% during the second quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock worth $32,000 after buying an additional 1,474 shares during the period. Larson Financial Group LLC increased its position in shares of Bicara Therapeutics by 1,015.5% during the third quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock valued at $62,000 after acquiring an additional 3,595 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in shares of Bicara Therapeutics by 419.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock valued at $44,000 after acquiring an additional 3,866 shares during the period.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.